Africa's health financing reset.

In just over a week, health ministers and senior officials from across the WHO African Region will meet in Addis Ababa for the Seventy-sixth session of the WHO Regional Committee for Africa.

Among the documents before them is a proposed Strategy for financing the future of health in the WHO African Region, 2026-2035.

The strategy is not specifically about antimicrobial resistance. But AMR may be one of the clearest tests of whether its ambitions can work in practice.

Why? Because AMR sits across many of the boundaries that make health financing difficult to understand: laboratories, surveillance, medicines, infection prevention and control, water and sanitation, primary health care, animal health, research, regulation, workforce capacity and national public-health systems.

Funding those capabilities is already complex. Tracing that funding to implementation and results is harder still.

The financing environment is changing

The proposed WHO African Region strategy starts from a difficult fiscal reality.

WHO describes health-financing systems across the Region as facing structural pressure from constrained public spending, high out-of-pocket expenditure, growing debt burdens and declining external assistance. The strategy consequently places renewed emphasis on domestic resource mobilization, stronger national ownership and more resilient financing systems.

Its proposed direction is significant. The strategy identifies seven broad areas for action, including stronger health-financing governance, revenue raising, pooling, strategic purchasing, public financial management and better integration of public-health functions and programmes.

It also explicitly includes strengthening evidence generation and accountability for results among its objectives.

AMR makes that question unusually visible.

AMR already has a financing mandate

The international AMR architecture has also moved. In May 2026, WHO Member States adopted the updated Global Action Plan on Antimicrobial Resistance 2026-2036.

The updated plan reinforces sustainable financing, accountability, monitoring and reporting and calls for countries to develop, implement and finance ambitious multisectoral national action plans.

Within the WHO African Region, the AMR programme similarly identifies capacity and financing as a core area of work, including increasing domestic investment and mobilizing external financing to accelerate national AMR action-plan implementation.

So the strategic direction is increasingly aligned: country ownership, implementation, financing and accountability.

The harder issue is operational.

Where exactly is the AMR capital?

Consider a national AMR action plan containing priorities such as expanding laboratory capacity, strengthening microbiological surveillance, improving antimicrobial stewardship, reducing healthcare-associated infections, strengthening medicine regulation, improving WASH infrastructure and developing workforce capabilities.

Now ask: How much capital is already supporting those priorities?

The answer may not sit in one AMR budget. Laboratory financing may be embedded within a health-security programme. Surveillance infrastructure may be financed through a broader disease-control project. Hospital infection-prevention activities may sit within quality-of-care budgets.

A development-bank health-system programme may strengthen capabilities critical to AMR without being labelled an AMR project. A donor grant may contain AMR-relevant components alongside many unrelated activities. Research funding may exist in an entirely separate system.

This creates an attribution problem. And attribution matters.

If every health-system investment with some relevance to AMR is counted as AMR financing, the resulting number can become misleadingly large. If only projects explicitly labelled AMR are counted, substantial enabling investment can disappear from view.

Neither extreme produces reliable decision intelligence.

Three categories are more useful than one number

A more defensible approach is to distinguish between different forms of capital.

Direct AMR capital is funding explicitly targeted at an AMR objective or intervention, such as a dedicated AMR surveillance programme, antimicrobial stewardship programme or AMR-specific research grant.

Enabling capital builds infrastructure or capabilities necessary for AMR action but serves broader health-system purposes. Laboratory networks, diagnostic infrastructure, infection-prevention systems or surveillance platforms can fall into this category depending on the programme.

Contextual capital covers broader investments that improve the health system but cannot reasonably be attributed to AMR without additional evidence.

The distinction is not merely semantic. It prevents a common analytical mistake: relevance being interpreted as attribution.

A 100 million dollar health-system programme containing one laboratory-strengthening component is not automatically 100 million dollars of AMR capital. But ignoring the programme entirely may also miss an important part of the country's AMR capability.

The analytical task is therefore not simply to find funding. It is to classify it.

Financing strategy needs evidence architecture

The proposed WHO AFRO financing strategy calls for stronger government institutional capacity, alignment of financing strategies with regional and global frameworks, mobilization and optimization of domestic resources and improved coordination of external financing to reduce fragmentation and duplication.

Those are financing functions. But they also create an information requirement.

To reduce duplication, someone must know what has already been financed. To align resources with national priorities, someone must be able to connect capital with those priorities. To improve accountability, someone must connect expenditure with implementation. To optimize resources, someone must identify overlap and gaps. And to measure results, someone must eventually connect implementation with observable outputs or outcomes.

In many health areas, pieces of that chain already exist. The problem is that they may exist in different databases, documents, institutions and reporting systems.

More funding cannot be the only metric

Imagine two countries.

Country A has received substantial international support for laboratories, surveillance and health security but cannot easily reconstruct which AMR priorities those investments cover.

Country B has received less total financing but can clearly identify its AMR priorities, existing funding, implementation status and remaining gaps.

Which country is better positioned to allocate the next dollar?

The answer is not necessarily the country with more data or even more funding. It may be the country with better capital visibility.

This becomes particularly important as external financing becomes more constrained and governments are asked to assume greater ownership of health investment. When capital is abundant, duplication is expensive. When capital is constrained, duplication becomes harder to justify.

Public visibility is not institutional reality

There is also a methodological warning.

If a researcher cannot identify a consolidated AMR financing line in publicly available sources, that does not demonstrate that no financing exists. Government ministries may have internal expenditure data. Donors may maintain programme-level financial information that is not publicly granular. AMR interventions may be distributed across departmental budgets. Implementation partners may maintain their own financial records.

Therefore, we could not identify the financing in the public evidence reviewed and the financing does not exist are not equivalent statements.

Maintaining that distinction is essential for credible institutional analysis. Unknown should remain unknown until better evidence becomes available.

The opportunity for RC76 is larger than AMR

The proposed financing strategy is designed for health systems as a whole, not for one disease area. WHO also states that the strategy cannot be costed centrally at regional level; country-specific policy choices, costs and resource mobilization will need to be determined with Member States.

That makes the country layer particularly important. AMR simply offers a useful case through which to examine the problem.

Can national priorities be connected to budgets? Can domestic and external financing be viewed together? Can enabling health-system investments be distinguished from directly attributable programme capital? Can duplication be identified? Can unfunded priorities be separated from priorities whose financing is merely difficult to observe? Can implementation evidence be connected back to the original investment?

Those questions are relevant far beyond AMR. They sit at the centre of effective public-health financing.

From financing commitments to financing intelligence

The policy direction heading into RC76 is increasingly clear: more sustainable domestic financing, greater country ownership, more efficient use of resources, better coordination of external capital and stronger accountability.

The next challenge is informational. A financing system cannot fully optimize what it cannot see.

For AMR, that means moving beyond the question how much funding is available? toward a more useful set of questions: what has already been financed, which national priorities that financing supports, where the genuine gaps are, what evidence exists that financed activities were implemented and what happened after implementation.

That is the difference between a funding landscape and a financing intelligence layer.

As health leaders gather in Addis Ababa, the financing debate deserves attention. For AMR, the next frontier may not simply be mobilizing additional capital. It may be making the path from priority to capital to implementation to proof visible enough to make better decisions.